ArticleJournal of virology2023
A multi-epitope/CXCL11 prime/pull coronavirus mucosal vaccine boosts the frequency and the function of lung-resident memory CD4
Open access · greenAbstract read
In one paragraph
Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.The Lancet. Microbe · 2023Trial
- Multi-antigen coronavirus vaccine induces potent and durable cross-protection against multiple SARS-CoV-2 variants.NPJ vaccines · 2026Article
- Review
- The Path Towards Effective Long-Lasting Tissue-Targeted Prime/Pull/Keep Herpes Simplex Therapeutic Vaccines.Vaccines · 2025Review
- A Multi-Antigen Broad-Spectrum Coronavirus Vaccine Induces Potent and Durable Cross-Protection Against Infection and Disease Caused by Multiple SARS-CoV-2 Variants.Research square · 2025Article
- Role of inflammasomes in cancer immunity: mechanisms and therapeutic potential.Journal of experimental & clinical cancer research : CR · 2025Review
- Tissue-Resident Memory CD8+ T Cells: Differentiation, Phenotypic Heterogeneity, Biological Function, Disease, and Therapy.MedComm · 2025Review
- Article
- Immunoinformatics design of a multi-epitope vaccine for Chlamydia trachomatis major outer membrane proteins.Scientific reports · 2024Article
- Safety and Immunogenicity Study of a Bivalent Vaccine for Combined Prophylaxis of COVID-19 and Influenza in Non-Human Primates.Vaccines · 2024Article
- Immunological Considerations for the Development of an Effective Herpes Vaccine.Microorganisms · 2024Review
- Therapeutic prime/pull vaccination of HSV-2-infected guinea pigs with the ribonucleotide reductase 2 (RR2) protein and CXCL11 chemokine boosts antiviral local tissue-resident and effector memory CD4Journal of virology · 2024Article
- A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster Model.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 2 countries.
Latifa ZayouLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA.ORCID 0009-0008-3049-4140
Swayam PrakashLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA.ORCID 0000-0003-3986-890X
Nisha Rajeswari DhanushkodiLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA.
Afshana QuadiriLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA.
Izabela Coimbra IbraimHigh containment facility, School of Medicine, University of California Irvine, Irvine, California, USA.
Mahmoud SingerLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA.
Amirah SalemLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA.
Amin Mohammed ShaikLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA.
Berfin SuzerLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA.
Amruth ChilukuriLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA.
Jennifer TranLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA.
Pauline Chau NguyenLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA.
Miyo SunLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA.
Kathy K Hormi-CarverLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA.
Ahmed BelmoudenLaboratory of Cell Biology and Molecular Genetics, Faculty of Sciences, Ibn Zohr University, Agadir, Morocco.
Hawa VahedDepartment of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, California, USA.
Daniel GilDepartment of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, California, USA.
Jeffrey B UlmerDepartment of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, California, USA.
Lbachir BenMohamedLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA.ORCID 0000-0001-9468-2521
University of California, Irvine · USUniversité Ibn Zohr · MA
Funding
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital HerpesR01AI150091 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Lbachir BenMohamed · 2020 to 2026
$4.0MDeveloping a Multi-epitope Pan-Coronavirus VaccineR01AI158060 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2020 to 2024
$3.7MMucosal Chemokines and CD8+ T Cell Immunity to Genital HerpesR01AI143348 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2022
$2.4MA Novel Multi-Epitope-Based Universal Vaccine Against Multiple Coronavirus Variants of ConcernR43AI174383 · NIAID · TECHIMMUNE, LLC · PI VAHED, HAWA · 2023 to 2024
$600kImpact of Immune Checkpoints Blockade on HSV-1 Neuro-PathogenesisR21AI143326 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2020
$464kLAT-HVEM Interactions Effect HSV-1 Latency/ReactivationR21AI110902 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2015 to 2016
$425kPROTECTIVE IMMUNITY AGAINST RECURRENT OCULAR HERPES INDUCED WITH SELF-ASSEMBLING PROTEIN NANOPARTICLESR21AI147499 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2020
$399kA NOVEL SELF-ASSEMBLING PROTEIN NANOPARTICLES-BASED GENITAL HERPES VACCINER41AI138764 · NIAID · SUNOMIX THERAPEUTICS · PI BENMOHAMED, LBACHIR · 2018 to 2018
$236kA NOVEL IMMUNO-PROTEOMIC APPROACH TO A GENITAL HERPES VACCINER43AI124911 · NIAID · IMMPORT THERAPEUTICS, INC. · PI LIANG, XIAOWU · 2016 to 2016
$225kNIAID NIH HHS R01 AI143348NIAID NIH HHS R01 AI150091NIAID NIH HHS R01 AI158060NIAID NIH HHS R21 AI110902NIAID NIH HHS R21 AI143326NIAID NIH HHS R21 AI147499NIAID NIH HHS R41 AI138764NIAID NIH HHS R43 AI124911NIAID NIH HHS R43 AI174383
Abstract
importanceAlthough the current rate of SARS-CoV-2 infections has decreased significantly, COVID-19 still ranks very high as a cause of death worldwide. As of October 2023, the weekly mortality rate is still at 600 deaths in the United States alone, which surpasses even the worst mortality rates recorded for influenza. Thus, the long-term outlook of COVID-19 is still a serious concern outlining the need for the next-generation vaccine. This study found that a prime/pull coronavirus vaccine strategy increased the frequency of functional SARS-CoV-2-specific CD4
Indexed as
COVID-19COVID-19 VaccinesAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesChemokine CXCL11Disease Models, AnimalEpitopesHumansLungMiceSARS-CoV-2Spike Glycoprotein, CoronavirusChemokine CXCL11COVID-19 VaccinesCXCL11 protein, humanEpitopesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2CD8+ T cellsCOVID-19CXCL-11lungsmemory CD4+SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.